FDA Approves Dovato for Teens Living With HIV
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 10, 2024 -- The U.S. Food and Drug Administration has approved Dovato (dolutegravir/lamivudine) for adolescents living with HIV.
The approval is for the treatment of HIV-1 infection in adolescents aged 12 years and older (weighing ≥25 kg) with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
The approval is based on data from the DANCE study, which evaluated Dovato in treatment-naive adolescents, as well as evidence from well-controlled trials in adults living with HIV, GEMINI-1 and GEMINI-2 (treatment-naive adults), and TANGO (treatment-experienced adults). The DANCE study demonstrated that 26 of 30 participants achieved and maintained viral suppression at week 48, with safety and efficacy in adolescents comparable to that seen in adults.
"This expanded indication for Dovato brings an oral, two-drug, single-tablet regimen to adolescents living with HIV, providing a complete HIV therapy with fewer ARV medicines -- an important consideration for young people who will require lifelong treatment," Lynn Baxter, head of North America at ViiV Healthcare, said in a statement.
Approval of Dovato was granted to ViiV Healthcare.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Recommendations Developed for People With HIV Wanting to Breastfeed
MONDAY, May 20, 2024 -- In an American Academy of Pediatrics clinical report published online May 20 in Pediatrics, recommendations are presented for breastfeeding among people...
Cognitive Impairment Still Seen in Children, Teens With HIV
TUESDAY, April 30, 2024 -- Cognitive impairment persists in children and adolescents living with HIV even in the era of antiretroviral therapy (ART), according to research...
Pandemic Reignited Debate Regarding Physician's Obligation to Treat
MONDAY, April 29, 2024 -- There was a surge in ethics literature during COVID-19 advocating for the ethical acceptability of physicians refusing to treat, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.